Insulinoma epidemiology and demographics: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
|||
| Line 2: | Line 2: | ||
{{CMG}}; {{AE}} {{ADS}} | {{CMG}}; {{AE}} {{ADS}} | ||
{{Insulinoma}} | {{Insulinoma}} | ||
==Overview== | ==Overview== | ||
| Line 8: | Line 7: | ||
==Epidemiology and Demographics== | ==Epidemiology and Demographics== | ||
===Incidence=== | ===Incidence=== | ||
*The incidence of insulinoma is approximately 0.1-0.4 per 100,000 individuals that constitute 1-2%of all pancreatic neoplasms.<ref name="pmid23430217">{{cite journal |vauthors=Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Ito S, Ogawa Y, Kobayashi M, Hanazaki K |title=Diagnosis and management of insulinoma |journal=World J. Gastroenterol. |volume=19 |issue=6 |pages=829–37 |year=2013 |pmid=23430217 |pmc=3574879 |doi=10.3748/wjg.v19.i6.829 |url=}}</ref><ref name="pmid1677058">{{cite journal |vauthors=Service FJ, McMahon MM, O'Brien PC, Ballard DJ |title=Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study |journal=Mayo Clin. Proc. |volume=66 |issue=7 |pages=711–9 |year=1991 |pmid=1677058 |doi= |url=}}</ref> | *The incidence of insulinoma is approximately 0.1-0.4 per 100,000 individuals that constitute 1-2% of all pancreatic neoplasms.<ref name="pmid23430217">{{cite journal |vauthors=Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Ito S, Ogawa Y, Kobayashi M, Hanazaki K |title=Diagnosis and management of insulinoma |journal=World J. Gastroenterol. |volume=19 |issue=6 |pages=829–37 |year=2013 |pmid=23430217 |pmc=3574879 |doi=10.3748/wjg.v19.i6.829 |url=}}</ref><ref name="pmid1677058">{{cite journal |vauthors=Service FJ, McMahon MM, O'Brien PC, Ballard DJ |title=Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study |journal=Mayo Clin. Proc. |volume=66 |issue=7 |pages=711–9 |year=1991 |pmid=1677058 |doi= |url=}}</ref> | ||
===Case-fatality rate=== | ===Case-fatality rate=== | ||
*In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate of [number range]%. | *In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate of [number range]%. | ||
| Line 29: | Line 22: | ||
*[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name]. | *[Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name]. | ||
===Gender=== | ===Gender=== | ||
* Females are more commonly affected by insulinoma than males. The female to male ratio is approximately 3:2. | * Females are more commonly (60-75%)<ref name="pmid1677058">{{cite journal |vauthors=Service FJ, McMahon MM, O'Brien PC, Ballard DJ |title=Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study |journal=Mayo Clin. Proc. |volume=66 |issue=7 |pages=711–9 |year=1991 |pmid=1677058 |doi= |url=}}</ref><ref anme =Škrha, J., Šváb, J., Krušina, L., Dušková, J., Hilgertová, J. & Keil, R. (2009). Diagnostics and | ||
treatment of organic hyperinsulinism – experience in 105 cases. Časopis Lékařů | |||
Českých| Vol. 148|Nr. 8 |pp. 389-394| ISSN 0008-7335</ref> affected by insulinoma than males. The female to male ratio is approximately 3:2. | |||
===Region=== | ===Region=== | ||
Revision as of 19:40, 8 September 2017
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Amandeep Singh M.D.[2]
|
Insulinoma Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Insulinoma epidemiology and demographics On the Web |
|
American Roentgen Ray Society Images of Insulinoma epidemiology and demographics |
|
Risk calculators and risk factors for Insulinoma epidemiology and demographics |
Overview
Epidemiology and Demographics
Incidence
- The incidence of insulinoma is approximately 0.1-0.4 per 100,000 individuals that constitute 1-2% of all pancreatic neoplasms.[1][2]
Case-fatality rate
- In [year], the incidence of [disease name] is approximately [number range] per 100,000 individuals with a case-fatality rate of [number range]%.
- The case-fatality rate of [disease name] is approximately [number range].
Age
- Patients of all age groups may develop [disease name].
- The incidence of [disease name] increases with age; the median age at diagnosis is [#] years.
- [Disease name] commonly affects individuals younger than/older than [number of years] years of age.
- [Chronic disease name] is usually first diagnosed among [age group].
- [Acute disease name] commonly affects [age group].
Race
- There is no racial predilection to [disease name].
- [Disease name] usually affects individuals of the [race 1] race. [Race 2] individuals are less likely to develop [disease name].
Gender
- Females are more commonly (60-75%)[2]<ref anme =Škrha, J., Šváb, J., Krušina, L., Dušková, J., Hilgertová, J. & Keil, R. (2009). Diagnostics and
treatment of organic hyperinsulinism – experience in 105 cases. Časopis Lékařů Českých| Vol. 148|Nr. 8 |pp. 389-394| ISSN 0008-7335</ref> affected by insulinoma than males. The female to male ratio is approximately 3:2.
Region
- The majority of [disease name] cases are reported in [geographical region].
- [Disease name] is a common/rare disease that tends to affect [patient population 1] and [patient population 2].
Developed Countries
Developing Countries
References
- ↑ Okabayashi T, Shima Y, Sumiyoshi T, Kozuki A, Ito S, Ogawa Y, Kobayashi M, Hanazaki K (2013). "Diagnosis and management of insulinoma". World J. Gastroenterol. 19 (6): 829–37. doi:10.3748/wjg.v19.i6.829. PMC 3574879. PMID 23430217.
- ↑ 2.0 2.1 Service FJ, McMahon MM, O'Brien PC, Ballard DJ (1991). "Functioning insulinoma--incidence, recurrence, and long-term survival of patients: a 60-year study". Mayo Clin. Proc. 66 (7): 711–9. PMID 1677058.